Cipla reported a significant decline in its consolidated net profit for the second quarter of FY27. The company's North American revenue fe...

Dr Reddy's domestic formulations business grew in the September quarter, while Revlimid sales declined in North America. A relaunch of gene...

In the second quarter of FY2027, Dr. Reddy's Labs experienced a downturn in both revenue and profit. However, the company supports new trad...

Dr Reddy’s Laboratories has expanded its generic semaglutide portfolio with Obeda Pro and Obeda Plus after supplies of its original Obeda i...

The last few weeks have made one thing clear. Oil prices, US bond yields, corporate earnings, and the state of the world – all point the sa...

Dr Reddy's Laboratories has received approval for Zytorvi, an immunotherapy targeting advanced esophageal squamous cell carcinoma. This new...

For millions of cancer patients, the cost of treatment can be as frightening as the diagnosis. From steep markups to patented drugs that re...

The next few weeks are critical, and one should not be in a hurry to make market-related decisions. Better to be cautious – to wait and wat...

Biocon announced a settlement with Genentech over its biosimilar, Pebrilzo, of the cancer drug Perjeta. The agreement allows Biocon to laun...

Biocon has finalized a global settlement and license agreement with Genentech for its drug Pebrilzo. This agreement addresses all ongoing l...

Kiran Mazumdar-Shaw emphasized the importance of building an innovation-driven pharmaceutical industry in India. She highlighted the need f...

An expert group is finalizing the list of cancer medicines for a new trade margin cap. The government plans to implement a 30% cap to reduc...

The Supreme Court has asked the government to address high markups on medicines and medical devices. The court questioned the decision to l...

Biocon chairperson Kiran Mazumdar-Shaw calls for greater use of digital technology to speed up drug development, as industry leaders push f...

The government is aiming to cap trade margins on anti-cancer medications at 30%. An expert committee has been tasked with compiling a repor...

Because each pharma company took a different road, they no longer rise and fall together. Where any one of them stands in 10 years depends ...

Indian pharmaceutical leaders emphasize the need for investment in innovation to transition from generics to innovative products. They high...